Aliceblue ANTInstall and trade smarter everywhere
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Akums Drugs & Pharmaceuticals Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
Key metrics and details at a glance.
Price Band
₹679
Per ShareLot Size
22 Shares
Minimum Investment
₹14,938
Issue Size
₹1,856.74 Cr
Face Value
₹2
Per ShareIPO Type
Book Building
Retail Quota
10%
QIB Quota
75%
NII Quota
15%
Important dates for your applying strategy.
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
82.44%
Issue Type
Book Building
ISIN
INE09XN01023
Bulkcorp International Limited is a pharmaceutical contract development and manufacturing organization offering a comprehensive range of pharmaceutical products and services in India and overseas. The Company is also engaged in the sale of branded pharmaceutical formulations and manufacturing of active pharmaceutical ingredients. Some of its other services include formulation research and development, preparation and filing of regulatory dossiers in the Indian and global markets, and other testing services. Some of its manufacturing units have been accredited by various global regulatory agencies such as the European Good Manufacturing Practice, the World Health Organization Good Manufacturing Practice and the United States National Sanitation Foundation.
The pharmaceutical industry in India is characterized by significant challenges, including, high capital expenditure required to establish and maintain sizeable manufacturing units, research and development expertise, trained manpower, consistent quality control, pricing pressure, disruptions within the supply chain, and the long-drawn regulatory and client approval and inspection processes, among others. An increase in chronic patient population, insurance penetration, trade generics, demand from tier II and III cities, and Government schemes focused on drug access are supporting growth in the Indian pharmaceutical market. Contract Development and Manufacturing Organizations assist pharmaceutical companies to employ an asset-light model and access global and specialized expertise while staying abreast with rapid innovation launches.
Revenue, profit after tax and total assets across the last 3 reported financial years.
Amount in ₹ crore
How the company plans to utilize IPO proceeds.
The funds raised through this IPO will be used for:
Initial public offer of 27,368,151* equity shares of face value of Rs. 2 each ("Equity Shares") of Akums Drugs and Pharmaceuticals Limited ("Company" or "Issuer") for cash at a price of Rs. 679^ per equity share (including a share premium of Rs. 677 per equity share) ("Offer Price") aggregating to Rs. 1856.74 crores*^ comprising a fresh issue of 10,037,716* equity shares aggregating to Rs. 680.00*^ crores by the company ("Fresh Issue") and an offer for sale of 17,330,435 equity shares aggregating to Rs. 1176.74 crores* ("Offered Shares") by the selling shareholders, comprising of 1,512,000 equity shares aggregating to Rs. 102.67 crores* by Sanjeev Jain, 1,512,000 equity shares aggregating to Rs. 102.67 crores* by Sandeep Jain (together the "Promoter Selling Shareholders") and 14,306,435 equity shares aggregating to Rs. 971.41 crores* by Ruby QC Investment Holdings Pte. Ltd. (The "Investor Selling Shareholder") (the promoter selling shareholders and the investor selling shareholder, collectively referred to as the "Selling Shareholders") ("Offer for Sale", together with the fresh issue, the "Offer"). This offer includes a reservation of 243,902* equity shares aggregating to Rs. 15.00 crores*^ for subscription by eligible employees (the "Employee Reservation Portion"). The offer less the employee reservation portion is hereinafter referred to as the "Net Offer". The offer and the net offer constituted 17.39% and 17.23% of its post-offer paid-up equity share capital, respectively. The face value of equity shares is Rs. 2 each. The offer price is 339.50 times the face value of the equity shares. *Subject to finalization of basis of allotment ^After employee discount.
*Subject to approvals and market conditions.
Key competitive advantages and factors to consider before investing.
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
The Company was incorporated as a public company, limited by shares, under the Companies Act, 1956, as amended, in the name of `Akums Drugs and Pharmaceuticals Limited', pursuant to a certificate of incorporation dated April 19, 2004 issued by the Registrar of Companies, Delhi and Haryana in New Delhi ("RoC"). The Company received a certificate of commencement of business issued by the RoC dated May 13, 2004.
Wholesaler and Retailer
Amount in ₹ crore
Amount in ₹ crore
Figures in ₹ crore, on a consolidated basis, as reported for FY24 to FY26.